Ledipasvir (BioDeep_00000672527)
代谢物信息卡片
Ledipasvir
化学式: C49H54F2N8O6 (888.4134168)
中文名称: 雷迪帕韦
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(C)C(C(=O)N1CC2(CC2)CC1C3=NC=C(N3)C4=CC5=C(C=C4)C6=C(C5(F)F)C=C(C=C6)C7=CC8=C(C=C7)N=C(N8)C9C1CCC(C1)N9C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC
InChI: InChI=1S/C49H54F2N8O6/c1-24(2)39(56-46(62)64-5)44(60)58-23-48(15-16-48)21-38(58)42-52-22-37(55-42)28-9-13-32-31-12-8-26(18-33(31)49(50,51)34(32)19-28)27-10-14-35-36(20-27)54-43(53-35)41-29-7-11-30(17-29)59(41)45(61)40(25(3)4)57-47(63)65-6/h8-10,12-14,18-20,22,24-25,29-30,38-41H,7,11,15-17,21,23H2,1-6H3,(H,52,55)(H,53,54)(H,56,62)(H,57,63)/t29-,30+,38-,39-,40-,41-/m0/s1
描述信息
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents
C254 - Anti-Infective Agent > C281 - Antiviral Agent
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:85089
- KEGGdrug: D10442
- PubChem: 67505836
- DrugBank: DB09027
- ChEMBL: CHEMBL2374220
- CAS: 1256388-51-8
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- K S Abdelkawy, Fathalla Belal, AbdelazizE Abdelaziz, H A Elmekawy, M Y Abdelgaied, N M El-Khodary. Statins Increase the Bioavailability of Fixed-Dose Combination of Sofosbuvir/Ledipasvir by Inhibition of P-glycoprotein.
Drug research.
2022 Jul; 72(6):319-326. doi:
10.1055/a-1835-1690. [PMID: 35724670] - Kathleen M Ward, Oluwaseun Falade-Nwulia, Juhi Moon, Catherine G Sutcliffe, Sherilyn Brinkley, Taryn Haselhuhn, Stephanie Katz, Kayla Herne, Lilian Arteaga, Shruti H Mehta, Carl Latkin, Robert K Brooner, Mark S Sulkowski. Nonadherence to Ledipasvir/Sofosbuvir Did Not Predict Sustained Virologic Response in a Randomized Controlled Trial of Human Immunodeficiency Virus/Hepatitis C Virus Coinfected Persons Who Use Drugs.
The Journal of infectious diseases.
2022 03; 225(5):903-911. doi:
10.1093/infdis/jiab477. [PMID: 34543417] - Mohamed Abdel-Salam Elgohary, Eman Medhat Hasan, Amany Ahmad Ibrahim, Mohamed Farouk Ahmed Abdelsalam, Raafat Zaher Abdel-Rahman, Ashraf Ibrahim Zaki, Mohamed Bakr Elaatar, Mohamed Thabet Elnagar, Mohamed Emam Emam, Mahmoud Moustafa Hamada, Taimour Mohamed Abdel-Hamid, Ahmad Samir Abdel-Hafez, Mohamed Gomaa Seadawy, Ahmad Rashad Fatoh, Mohamed Ali Elsaied, Marwa Abdel-Rahman Sakr, Ahmed Omar Elkady, Mohamed Muawad Shehata, Osama Mohamed Nawar, Mohamed Abu-Elnaga Selem, Mohamed Saeed Abd-Aal, Hany Hafez Lotfy, Tarek Refaat Elnagdy, Sherine Helmy, Magdy Amin Mubark. Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial.
Journal of medicine and life.
2022 Mar; 15(3):350-358. doi:
10.25122/jml-2021-0175. [PMID: 35449996] - Hanan I El-Shorbagy, Fathalla Belal. Innovative derivative/zero ratio spectrophotometric method for simultaneous determination of sofosbuvir and ledipasvir: Application to average content and uniformity of dosage units.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.
2022 Feb; 267(Pt 2):120623. doi:
10.1016/j.saa.2021.120623. [PMID: 34810100] - Supriyo Saha, Gyu Seong Yeom, Satish Balasaheb Nimse, Dilipkumar Pal. Combination Therapy of Ledipasvir and Itraconazole in the Treatment of COVID-19 Patients Coinfected with Black Fungus: An In Silico Statement.
BioMed research international.
2022; 2022(?):5904261. doi:
10.1155/2022/5904261. [PMID: 35463967] - Feroza Begum, Amit Kumar Srivastava, Upasana Ray. Repurposing nonnucleoside antivirals against SARS-CoV2 NSP12 (RNA dependent RNA polymerase): In silico-molecular insight.
Biochemical and biophysical research communications.
2021 09; 571(?):26-31. doi:
10.1016/j.bbrc.2021.07.050. [PMID: 34303192] - Wan-Long Chuang, Tsung-Hui Hu, Peter Buggisch, Christophe Moreno, Wei-Wen Su, Luigi Biancone, Marianne Camargo, Robert Hyland, Sophia Lu, Brian J Kirby, Hadas Dvory-Sobol, Anu Osinusi, Anuj Gaggar, Cheng-Yuan Peng, Chen-Hua Liu, Meghan E Sise, Alessandra Mangia. Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal Disease.
The American journal of gastroenterology.
2021 09; 116(9):1924-1928. doi:
10.14309/ajg.0000000000001281. [PMID: 34465694] - Mohamed A Abdel-Lateef, Mahmoud A Omar, Ramadan Ali, Albandary Almahri, Sayed M Derayea. Innovative Thin-Layer Chromatography/Fluorescence Detection Approach for Sensitive and Specific Determination of Ledipasvir in Rats' Feces and Pharmaceutical Dosage Form.
Journal of chromatographic science.
2021 Jun; 59(7):634-641. doi:
10.1093/chromsci/bmab019. [PMID: 33634316] - Rameez Hassan Pirzada, Muhammad Haseeb, Maria Batool, MoonSuk Kim, Sangdun Choi. Remdesivir and Ledipasvir among the FDA-Approved Antiviral Drugs Have Potential to Inhibit SARS-CoV-2 Replication.
Cells.
2021 04; 10(5):. doi:
10.3390/cells10051052. [PMID: 33946869] - Hung-Chih Chiu, Yen-Cheng Chiu, Er-Hsiang Yang, Ting-Tsung Chang, Shih-Chieh Chien, I-Chin Wu, Chun-Hsien Wu, Pin-Nan Cheng. Effectiveness and safety of ledipasvir/sofosbuvir for genotype 2 chronic hepatitis C infection: Real-world experience from Taiwan.
Journal of the Formosan Medical Association = Taiwan yi zhi.
2021 Mar; 120(3):983-990. doi:
10.1016/j.jfma.2020.08.033. [PMID: 32891488] - Mohammad Bagher Majnooni, Seid-Shahram Miraghaee, Samira Keshavarzi, Bahareh Mohammadi, Soraya Sajadimajd, Razieh Hatami, Gholamreza Bahrami. Rapid and sensitive UHPLC-DAD method for simultaneous determination of sofosbuvir and ledipasvir in human serum.
Journal of pharmaceutical and biomedical analysis.
2021 Feb; 195(?):113860. doi:
10.1016/j.jpba.2020.113860. [PMID: 33387837] - Eloi Chevallier, Matthias Büchler, Sophie Caillard, Nicolas Bouvier, Charlotte Colosio, Joseph Rivalan, Johnny Sayegh, Dominique Bertrand, Yannick Le Meur, Antoine Thierry, Cyril Garrouste, Jean-Philippe Rerolle, Lionel Rostaing, Philippe Gatault. Chronic Hepatitis C Virus Infection After Kidney Transplantation With or Without Direct-Acting Antivirals in a Real-Life Setting: A French Multicenter Experience.
Transplantation proceedings.
2020 Dec; 52(10):3179-3185. doi:
10.1016/j.transproceed.2020.06.005. [PMID: 32636068] - Kristina M Brooks, Jose R Castillo-Mancilla, Mary Morrow, Samantha MaWhinney, Joshua Blum, David L Wyles, Sarah E Rowan, Mustafa E Ibrahim, Jia-Hua Zheng, Bethany Johnson, Joe Gomez, Ye Ji Choi, Francesca Cendali, Hannah Haas, Laura Roon, Lane R Bushman, Peter L Anderson, Jennifer J Kiser. Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir.
The Journal of antimicrobial chemotherapy.
2020 11; 75(11):3303-3310. doi:
10.1093/jac/dkaa299. [PMID: 32766700] - Sabela Lens, Mireia Miquel, Beatriz Mateos-Muñoz, Javier García-Samaniego, Xavier Forns. SARS-CoV-2 in patients on antiviral HBV and HCV therapy in Spain.
Journal of hepatology.
2020 11; 73(5):1262-1263. doi:
10.1016/j.jhep.2020.07.007. [PMID: 32673740] - Amal E Hamad, Bassam Shaaban Mohammed, Sayed M Derayea, Samah F El-Malla. Micelle sensitized synchronous spectrofluorimetric approaches for the simultaneous determination of simeprevir and ledipasvir: Application to pharmaceutical formulations and human plasma.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.
2020 Oct; 239(?):118471. doi:
10.1016/j.saa.2020.118471. [PMID: 32474370] - Annette Bruchfeld. HCV eradication in chronic kidney disease: ready for prime time?.
The lancet. Gastroenterology & hepatology.
2020 10; 5(10):880-882. doi:
10.1016/s2468-1253(20)30015-7. [PMID: 32531258] - Savneek Chugh, Shantanu Solanki, Jagmeet Singh, David C Wolf, Praveen N Chander. Acute Renal Failure in a Patient on Ledipasvir-Sofosbuvir Therapy for Hepatitis C.
American journal of therapeutics.
2020 07; 28(6):e755-e757. doi:
10.1097/mjt.0000000000001144. [PMID: 32759622] - Mohamed A Abdel-Lateef, Ramadan Ali, Mahmoud A Omar, Sayed M Derayea. Micellar-based spectrofluorimetric method for the selective determination of ledipasvir in the presence of sofosbuvir: application to dosage forms and human plasma.
Luminescence : the journal of biological and chemical luminescence.
2020 Jun; 35(4):486-492. doi:
10.1002/bio.3753. [PMID: 31869004] - Jyh-Jou Chen, Pei-Lun Lee, Hung-Chih Chiu, Hung-Da Tung, Yen-Cheng Chiu, Pin-Nan Cheng. Real-world effectiveness and safety of ledipasvir/sofosbuvir for genotype 6 chronic hepatitis C patients in Taiwan.
Journal of gastroenterology and hepatology.
2020 Mar; 35(3):467-472. doi:
10.1111/jgh.14845. [PMID: 31445507] - Cuiyun Li, Xiaojiao Li, Xiaoxue Zhu, Hong Zhang, Gong Shen, Kathryn Kersey, Yanhua Ding. Pharmacokinetics, Safety, and Tolerability of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Healthy Chinese Subjects.
Clinical therapeutics.
2020 03; 42(3):448-457. doi:
10.1016/j.clinthera.2020.01.013. [PMID: 32115243] - Yuhei Saito, Michio Imamura, Takuro Uchida, Mitsutaka Osawa, Yuji Teraoka, Hatsue Fujino, Takashi Nakahara, Atsushi Ono, Eisuke Murakami, Tomokazu Kawaoka, Daiki Miki, Masataka Tsuge, Masahiro Serikawa, Hiroshi Aikata, Hiromi Abe-Chayama, C Nelson Hayes, Kazuaki Chayama. Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy.
Journal of medical virology.
2020 02; 92(2):210-218. doi:
10.1002/jmv.25602. [PMID: 31584207] - Prasanta Debnath, Sanjay Chandnani, Pravin Rathi, Sujit Nair, Vinay Pawar, Qais Contractor. COMBINED NS5A & NS5B NUCLEOTIDE INHIBITOR THERAPY FOR PATIENTS WITH CHRONIC HEPATITIS C WITH STAGE 5 CHRONIC KIDNEY DISEASE ON HEMODIALYSIS.
Arquivos de gastroenterologia.
2020 Jan; 57(1):39-44. doi:
10.1590/s0004-2803.202000000-08. [PMID: 32294734] - Ting Lin, Xipei Wang, Hongbo Gao, Zhonglin Feng, Lixia Xu, Jianchao Ma, Zhuo Li, Li Zhang, Renwei Huang, Xinling Liang, Shuangxin Liu. Effect of Hemodialysis on Efficacy and Pharmacokinetics of Sofosbuvir Coformulated with Either Daclatasvir or Ledipasvir in Patients with End-Stage Renal Disease.
Blood purification.
2020; 49(6):692-699. doi:
10.1159/000499161. [PMID: 32289799] - Yu Wai Chen, Chin-Pang Bennu Yiu, Kwok-Yin Wong. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates.
F1000Research.
2020; 9(?):129. doi:
10.12688/f1000research.22457.2. [PMID: 32194944] - L M Lawson-Ananissoh, Ya Henriette K Anzouan-Kacou, Y M Tsevi, Kan C Ackoundou-N'Guessan, K A Attia. Effectiveness of the Treatment of Chronic Hepatitis C Virus Infection Genotype 2 by the Combination Sofosbuvir/Ledipasvir in a Black African Kidney Transplant.
West African journal of medicine.
2019 Sep; 36(3):280-282. doi:
NULL. [PMID: 31622492] - Kristina M Brooks, Jose R Castillo-Mancilla, Joshua Blum, Ryan Huntley, Samantha MaWhinney, Keisha Alexander, Becky Jo Kerr, Lucas Ellison, Lane R Bushman, Christine E MacBrayne, Peter L Anderson, Jennifer J Kiser. Increased tenofovir monoester concentrations in patients receiving tenofovir disoproxil fumarate with ledipasvir/sofosbuvir.
The Journal of antimicrobial chemotherapy.
2019 08; 74(8):2360-2364. doi:
10.1093/jac/dkz184. [PMID: 31081036] - Lucio Boglione, Amedeo De Nicolò, Giovanni Di Perri, Antonio D'Avolio. Flecainide plasma level modifications during ledipasvir/sofosbuvir coadministration in two patients affected by chronic hepatitis C.
Antiviral therapy.
2019; 24(7):553-555. doi:
10.3851/imp3328. [PMID: 31502554] - Fatma A M Abdel-Aal, Azza H Rageh, Mohamed I Said, Gamal A Saleh. ε-MnO2-modified graphite electrode as a novel electrochemical sensor for the ultrasensitive detection of the newly FDA approved Hepatitis C antiviral drug ledipasvir.
Analytica chimica acta.
2018 Dec; 1038(?):29-40. doi:
10.1016/j.aca.2018.07.018. [PMID: 30278905] - Manoj Kumar, Suman L Nayak, Ekta Gupta, Ashish Kataria, Shiv K Sarin. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
Liver international : official journal of the International Association for the Study of the Liver.
2018 12; 38(12):2137-2148. doi:
10.1111/liv.13863. [PMID: 29676846] - Ehab F Elkady, Ahmed A Aboelwafa. Rapid bioanalytical LC-MS/MS method for the simultaneous determination of sofosbuvir and velpatasvir in human plasma-application to a pharmacokinetic study in Egyptian volunteers.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2018 Dec; 1102-1103(?):116-124. doi:
10.1016/j.jchromb.2018.10.020. [PMID: 30384188] - Keiji Tsuji, Masayuki Kurosaki, Jun Itakura, Nami Mori, Shintaro Takaki, Chitomi Hasebe, Takehiro Akahane, Kouji Joko, Hitoshi Yagisawa, Jirou Takezawa, Ryou Nakata, Atsunori Kusakabe, Yuji Kojima, Hiroyuki Kimura, Takashi Tamada, Haruhiko Kobashi, Akeri Mitsuda, Masahiko Kondou, Chikara Ogawa, Yasushi Uchida, Tetsuro Sohda, Ryouichi Narita, Namiki Izumi. Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group.
Journal of gastroenterology.
2018 Oct; 53(10):1142-1150. doi:
10.1007/s00535-018-1455-1. [PMID: 29626296] - Ramadan Ali, Adel A Marzouk, Reda A Abdelhameid, Mahmoud A Omar. Specific stability indicating spectrofluorimetric method for determination of ledipasvir in the presence of its confirmed degradation products; application in human plasma.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.
2018 Sep; 202(?):50-57. doi:
10.1016/j.saa.2018.05.044. [PMID: 29777934] - Ola M Abdallah, Ahmed M Abdel-Megied, Amira S Gouda. Pharmacokinetic evaluation of daclatasvir and ledipasvir in healthy volunteers using a validated highly sensitive spectrofluorimetric method.
Luminescence : the journal of biological and chemical luminescence.
2018 Sep; 33(6):1094-1100. doi:
10.1002/bio.3514. [PMID: 30047624] - NULL. 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C.
Clinical and molecular hepatology.
2018 09; 24(3):169-229. doi:
10.3350/cmh.2018.1004. [PMID: 30092624] - Sunil Taneja, Ajay Duseja, Arka De, Vivek Kumar, Raja Ramachandran, Ashish Sharma, Radha K Dhiman, Krishan L Gupta, Yogesh Chawla. Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients.
Nephrology (Carlton, Vic.).
2018 Sep; 23(9):876-882. doi:
10.1111/nep.13109. [PMID: 28703905] - Jessica L Michal, Saira Rab, Manish Patel, Alison W Kyle, Lesley S Miller, Kirk A Easley, Aley G Kalapila. Incidence of Acute Kidney Injury in Patients Coinfected with HIV and Hepatitis C Virus Receiving Tenofovir Disoproxil Fumarate and Ledipasvir/Sofosbuvir in a Real-World, Urban, Ryan White Clinic.
AIDS research and human retroviruses.
2018 08; 34(8):690-698. doi:
10.1089/aid.2017.0271. [PMID: 29766745] - Polina German, Anita Mathias, Diana M Brainard, Qinghua Song, John Ling, Brian P Kearney. A Thorough QT Study to Evaluate the Effects of Supratherapeutic Doses of Ledipasvir on the QTc Interval in Healthy Subjects.
Clinical pharmacology in drug development.
2018 08; 7(6):641-651. doi:
10.1002/cpdd.390. [PMID: 29058821] - W Abdel-Razek, I Waked. Editorial: is sofosbuvir-based therapy suitable for patients with advanced chronic kidney disease?.
Alimentary pharmacology & therapeutics.
2018 08; 48(3):379-380. doi:
10.1111/apt.14831. [PMID: 29998505] - A A Butt, Y Ren, A Puenpatom, J M Arduino, R Kumar, A-B Abou-Samra. Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study.
Alimentary pharmacology & therapeutics.
2018 07; 48(1):35-43. doi:
10.1111/apt.14799. [PMID: 29797514] - Mohamed M El-Wekil, Ashraf M Mahmoud, Saad A Alkahtani, Adel A Marzouk, Ramadan Ali. A facile synthesis of 3D NiFe2O4 nanospheres anchored on a novel ionic liquid modified reduced graphene oxide for electrochemical sensing of ledipasvir: Application to human pharmacokinetic study.
Biosensors & bioelectronics.
2018 Jun; 109(?):164-170. doi:
10.1016/j.bios.2018.03.015. [PMID: 29554476] - Sarah E Kleinstein, Patrick R Shea, Luisa M Stamm, Mark Sulkowski, David B Goldstein, Susanna Naggie. Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2018 06; 66(12):1953-1956. doi:
10.1093/cid/cix1051. [PMID: 29522085] - Mohammed Shujauddin Akhil, Balaji Kirushnan, Melvin Martin, Kanakaraj Arumugam, N K Ganesh Prasad, Rajan Ravichandran. Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.
Nephrology (Carlton, Vic.).
2018 May; 23(5):446-452. doi:
10.1111/nep.13050. [PMID: 28339162] - Mohammad Nabil Abo-Zeid, Noha N Atia, Samia M El-Gizawy, Salwa R El-Shaboury. Ultrasensitive spectrofluorimetric method for rapid determination of daclatasvir and ledipasvir in human plasma and pharmaceutical formulations.
Journal of pharmaceutical and biomedical analysis.
2018 Apr; 152(?):155-164. doi:
10.1016/j.jpba.2018.01.038. [PMID: 29414007] - Mandarapu Surendra, Sree Bhushan Raju, Nimmagadda Sridhar, Bangillapati Vijay Kiran, Goli Rajesh, Golla Anvesh, Nallagasu Raju. Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection in end stage renal disease patients: A prospective observational study.
Hemodialysis international. International Symposium on Home Hemodialysis.
2018 04; 22(2):217-221. doi:
10.1111/hdi.12604. [PMID: 28972699] - E Rosenthal, C Fougerou-Leurent, A Renault, M P Carrieri, F Marcellin, R Garraffo, E Teicher, H Aumaitre, K Lacombe, F Bailly, E Billaud, S Chevaliez, S Dominguez, M A Valantin, J Reynes, A Naqvi, L Cotte, S Metivier, V Leroy, M Dupon, T Allegre, P De Truchis, V Jeantils, J Chas, D Salmon-Ceron, P Morlat, D Neau, P Perré, L Piroth, S Pol, M Bourlière, G P Pageaux, L Alric, D Zucman, P M Girard, I Poizot-Martin, Y Yazdanpanah, F Raffi, E Le Pabic, C Tual, A Pailhé, I Amri, E Bellissant, J M Molina. Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study).
HIV medicine.
2018 03; 19(3):227-237. doi:
10.1111/hiv.12571. [PMID: 29214737] - Caroline Solas, Sylvie Bregigeon, Olivia Faucher-Zaegel, Sylvie Quaranta, Véronique Obry-Roguet, Catherine Tamalet, Bruno Lacarelle, Isabelle Poizot-Martin. Ledipasvir and tenofovir drug interaction in human immunodeficiency virus-hepatitis C virus coinfected patients: Impact on tenofovir trough concentrations and renal safety.
British journal of clinical pharmacology.
2018 02; 84(2):404-409. doi:
10.1111/bcp.13450. [PMID: 29028125] - K M Kitrinos, A C Corsa, A Worth, C Hedskog, D M Brainard, M D Miller, H Mo. Nonstructural protein 5A resistance profile in patients with chronic hepatitis C treated with ledipasvir-containing regimens without sofosbuvir.
Journal of viral hepatitis.
2018 02; 25(2):126-133. doi:
10.1111/jvh.12783. [PMID: 28833932] - Rajiv Mehta, Ketan Desai, Mayank Kabrawala, Subhash Nandwani, Jatin Shah, Nisha Desai, Viral Parekh. Preliminary experience with sofosbuvir-based treatment regimens for patients dependent on hemodialysis.
Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology.
2018 01; 37(1):72-73. doi:
10.1007/s12664-018-0833-1. [PMID: 29430587] - Adeel Ajwad Butt, Peng Yan, Tracey G Simon, Abdul-Badi Abou-Samra. Effect of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir and Ledipasvir/Sofosbuvir Regimens on Survival Compared With Untreated Hepatitis C Virus-Infected Persons: Results From ERCHIVES.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2017 Sep; 65(6):1006-1011. doi:
10.1093/cid/cix364. [PMID: 28903508] - Ola M Abdallah, Ahmed M Abdel-Megied, Amira S Gouda. Development a validated highly sensitive LC-MS/MS method for simultaneous quantification of Ledipasvir, sofosbuvir and its major metabolite GS-331007 in human plasma: Application to a human pharmacokinetic study.
Journal of pharmaceutical and biomedical analysis.
2017 Sep; 143(?):305-310. doi:
10.1016/j.jpba.2017.06.005. [PMID: 28645021] - Kalyan R Bhamidimarri, Marco Ladino, Fernando Pedraza, Giselle Guerra, Adela Mattiazzi, Linda Chen, Gaetano Ciancio, Warren Kupin, Paul Martin, George Burke, David Roth. Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.
Transplant international : official journal of the European Society for Organ Transplantation.
2017 Sep; 30(9):865-873. doi:
10.1111/tri.12954. [PMID: 28332729] - Yoshihide Ueda, Toru Ikegami, Nobuhisa Akamatsu, Akihiko Soyama, Masahiro Shinoda, Ryoichi Goto, Hideaki Okajima, Tomoharu Yoshizumi, Akinobu Taketomi, Yuko Kitagawa, Susumu Eguchi, Norihiro Kokudo, Shinji Uemoto, Yoshihiko Maehara. Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience.
Journal of gastroenterology.
2017 Aug; 52(8):986-991. doi:
10.1007/s00535-017-1310-9. [PMID: 28138756] - A A Pillai, R Maheshwari, R Vora, J P Norvell, R Ford, S Parekh, N Cheng, A Patel, N Young, J R Spivey, O Mgbemena, J P Wedd. Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin.
Alimentary pharmacology & therapeutics.
2017 06; 45(11):1427-1432. doi:
10.1111/apt.14059. [PMID: 28382751] - Ute Eisenberger, Hana Guberina, Katharina Willuweit, Anja Bienholz, Andreas Kribben, Guido Gerken, Oliver Witzke, Kerstin Herzer. Successful Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Ledipasvir in Renal Transplant Recipients.
Transplantation.
2017 05; 101(5):980-986. doi:
10.1097/tp.0000000000001414. [PMID: 27495770] - Ashesh P Shah, Andrew Cameron, Pooja Singh, Adam M Frank, Jonathan M Fenkel. Successful treatment of donor-derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens.
Transplant infectious disease : an official journal of the Transplantation Society.
2017 Apr; 19(2):. doi:
10.1111/tid.12660. [PMID: 28060446] - Gabriele Fabbri, Ilaria Mastrorosa, Alessandra Vergori, Valentina Mazzotta, Carmela Pinnetti, Susanna Grisetti, Mauro Zaccarelli, Adriana Ammassari, Andrea Antinori. Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature.
BMC infectious diseases.
2017 03; 17(1):182. doi:
10.1186/s12879-017-2287-y. [PMID: 28249574] - Brigitta Globke, Nathanael Raschzok, Eva-Maria Teegen, Johann Pratschke, Eckart Schott, Dennis Eurich. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
Transplant infectious disease : an official journal of the Transplantation Society.
2017 Feb; 19(1):. doi:
10.1111/tid.12647. [PMID: 27943544] - Sandra Elmasry, Sanya Wadhwa, Bo-Ram Bang, Linda Cook, Shefali Chopra, Gary Kanel, Brian Kim, Tammy Harper, Zongdi Feng, Keith R Jerome, Jeffrey A Kahn, Takeshi Saito. Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents for Recurrent Infection After Liver Transplantation.
Gastroenterology.
2017 02; 152(3):550-553.e8. doi:
10.1053/j.gastro.2016.11.002. [PMID: 27838287] - Massimo Colombo, Alessio Aghemo, Hong Liu, Jie Zhang, Hadas Dvory-Sobol, Robert Hyland, Chohee Yun, Benedetta Massetto, Diana M Brainard, John G McHutchison, Marc Bourlière, Markus Peck-Radosavljevic, Michael Manns, Stanislas Pol. Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial.
Annals of internal medicine.
2017 Jan; 166(2):109-117. doi:
10.7326/m16-1205. [PMID: 27842383] - Mark R Pedersen, Amit Patel, David Backstedt, Myunghan Choi, Anil B Seetharam. Genotype specific peripheral lipid profile changes with hepatitis C therapy.
World journal of gastroenterology.
2016 Dec; 22(46):10226-10231. doi:
10.3748/wjg.v22.i46.10226. [PMID: 28028371] - Jason Grebely, Stefan Mauss, Ashley Brown, Jean-Pierre Bronowicki, Massimo Puoti, David Wyles, Macky Natha, Yanni Zhu, Junming Yang, Bruce Kreter, Diana M Brainard, Chohee Yun, Val Carr, Gregory J Dore. Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2016 Dec; 63(11):1405-1411. doi:
10.1093/cid/ciw580. [PMID: 27553375] - M A Gentil, C González-Corvillo, M Perelló, S Zarraga, C Jiménez-Martín, L R Lauzurica, A Alonso, A Franco, D Hernández-Marrero, A Sánchez-Fructuoso. Hepatitis C Treatment With Direct-Acting Antivirals in Kidney Transplant: Preliminary Results From a Multicenter Study.
Transplantation proceedings.
2016 Nov; 48(9):2944-2946. doi:
10.1016/j.transproceed.2016.07.034. [PMID: 27932113] - Pegah Golabi, Elzafir Elsheikh, Azza Karrar, James M Estep, Issah Younossi, Maria Stepanova, Lynn Gerber, Zobair M Younossi. The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV).
Medicine.
2016 Nov; 95(46):e5066. doi:
10.1097/md.0000000000005066. [PMID: 27861337] - George Lau, Yves Benhamou, Guofeng Chen, Jin Li, Qing Shao, Dong Ji, Fan Li, Bing Li, Jialiang Liu, Jinlin Hou, Jian Sun, Cheng Wang, Jing Chen, Vanessa Wu, April Wong, Chris L P Wong, Stella T Y Tsang, Yudong Wang, Leda Bassit, Sijia Tao, Yong Jiang, Hui-Mien Hsiao, Ruian Ke, Alan S Perelson, Raymond F Schinazi. Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.
The lancet. Gastroenterology & hepatology.
2016 10; 1(2):97-104. doi:
10.1016/s2468-1253(16)30015-2. [PMID: 27917405] - Ehab F Elkady, Ahmed A Aboelwafa. A Rapid and Optimized LC-MS/MS Method for the Simultaneous Extraction and Determination of Sofosbuvir and Ledipasvir in Human Plasma.
Journal of AOAC International.
2016 Sep; 99(5):1252-9. doi:
10.5740/jaoacint.16-0021. [PMID: 27480956] - Sandra Beinhardt, Ramona Al Zoairy, Peter Ferenci, Karin Kozbial, Clarissa Freissmuth, Rafael Stern, Albert Friedrich Stättermayer, Rudolf Stauber, Michael Strasser, Heinz Zoller, Bruno Watschinger, Alice Schmidt, Michael Trauner, Harald Hofer, Andreas Maieron. DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting.
Transplant international : official journal of the European Society for Organ Transplantation.
2016 Sep; 29(9):999-1007. doi:
10.1111/tri.12799. [PMID: 27203857] - Kristen L Bunnell, Sonia Vibhakar, Robert C Glowacki, Maureen A Gallagher, Albert M Osei, Gregory Huhn. Nephrotoxicity Associated with Concomitant Use of Ledipasvir-Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection.
Pharmacotherapy.
2016 09; 36(9):e148-53. doi:
10.1002/phar.1803. [PMID: 27459733] - Mamdouh R Rezk, Ehab R Bendas, Emad B Basalious, Iman A Karim. Quantification of sofosbuvir and ledipasvir in human plasma by UPLC-MS/MS method: Application to fasting and fed bioequivalence studies.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2016 Aug; 1028(?):63-70. doi:
10.1016/j.jchromb.2016.06.004. [PMID: 27322631] - Tavankit Singh, John Guirguis, Sumi Anthony, John Rivas, Ibrahim A Hanouneh, Naim Alkhouri. Sofosbuvir-based treatment is safe and effective in patients with chronic hepatitis C infection and end stage renal disease: a case series.
Liver international : official journal of the International Association for the Study of the Liver.
2016 06; 36(6):802-6. doi:
10.1111/liv.13078. [PMID: 26824848] - Kerry Townsend, Eric G Meissner, Sreetha Sidharthan, Maureen Sampson, Alan T Remaley, Lydia Tang, Anita Kohli, Anu Osinusi, Henry Masur, Shyam Kottilil. Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration.
AIDS research and human retroviruses.
2016 May; 32(5):456-62. doi:
10.1089/aid.2015.0170. [PMID: 26559180] - Adeel A Butt, Peng Yan, Obaid S Shaikh, Raymond T Chung, Kenneth E Sherman. Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES.
Liver international : official journal of the International Association for the Study of the Liver.
2016 05; 36(5):651-8. doi:
10.1111/liv.13036. [PMID: 26616353] - Christopher M Jensen, Lisa M Holle. Ledipasvir-Sofosbuvir: A Once-Daily Oral Treatment Option for Chronic Hepatitis C Virus Genotype 1 Infection.
Pharmacotherapy.
2016 05; 36(5):562-74. doi:
10.1002/phar.1748. [PMID: 27027412] - Armand Abergel, Tarik Asselah, Sophie Metivier, Kathryn Kersey, Deyuan Jiang, Hongmei Mo, Phillip S Pang, Didier Samuel, Véronique Loustaud-Ratti. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.
The Lancet. Infectious diseases.
2016 Apr; 16(4):459-64. doi:
10.1016/s1473-3099(15)00529-0. [PMID: 26803446] - Sarah Kattakuzhy, Eleanor Wilson, Sreetha Sidharthan, Zayani Sims, Mary McLaughlin, Angie Price, Rachel Silk, Chloe Gross, Elizabeth Akoth, Maryellen McManus, Benjamin Emmanuel, Shikha Shrivastava, Lydia Tang, Amy Nelson, Gebeyehu Teferi, Jose Chavez, Brian Lam, Hongmei Mo, Anuoluwapo Osinusi, Michael A Polis, Henry Masur, Anita Kohli, Shyamasundaran Kottilil. Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2016 Feb; 62(4):440-447. doi:
10.1093/cid/civ897. [PMID: 26503379] - Chenwei Pan, Yongping Chen, Weilai Chen, Guangyao Zhou, Lingxiang Jin, Yi Zheng, Wei Lin, Zhenzhen Pan. Simultaneous determination of ledipasvir, sofosbuvir and its metabolite in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2016 Jan; 1008(?):255-259. doi:
10.1016/j.jchromb.2015.11.056. [PMID: 26684720] - Edward J Gane, Robert H Hyland, Di An, Evguenia S Svarovskaia, Diana Brainard, John G McHutchison. Ledipasvir and sofosbuvir for HCV infection in patients coinfected with HBV.
Antiviral therapy.
2016; 21(7):605-609. doi:
10.3851/imp3066. [PMID: 27367295] - Guo-Feng Chen, Lai Wei, Jing Chen, Zhong-Ping Duan, Xiao-Guang Dou, Qing Xie, Wen-Hong Zhang, Lun-Gen Lu, Jian-Gao Fan, Jun Cheng, Gui-Qiang Wang, Hong Ren, Jiu-Ping Wang, Xing-Xiang Yang, Zhan-Sheng Jia, Qing-Chun Fu, Xiao-Jin Wang, Jia Shang, Yue-Xin Zhang, Ying Han, Ning Du, Qing Shao, Dong Ji, Fan Li, Bing Li, Jia-Liang Liu, Xiao-Xia Niu, Cheng Wang, Vanessa Wu, April Wong, Yu-Dong Wang, Jin-Lin Hou, Ji-Dong Jia, Hui Zhuang, George Lau. Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data.
PloS one.
2016; 11(6):e0155934. doi:
10.1371/journal.pone.0155934. [PMID: 27276081] - Lynn Gerber, Michael Estep, Maria Stepanova, Carey Escheik, Ali Weinstein, Zobair M Younossi. Effects of Viral Eradication With Ledipasvir and Sofosbuvir, With or Without Ribavirin, on Measures of Fatigue in Patients With Chronic Hepatitis C Virus Infection.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
2016 Jan; 14(1):156-64.e3. doi:
10.1016/j.cgh.2015.07.035. [PMID: 26241510] - Z M Younossi, E Elsheikh, M Stepanova, L Gerber, F Nader, L M Stamm, D M Brainard, J G McHutchinson. Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels.
Journal of viral hepatitis.
2015 Dec; 22(12):977-82. doi:
10.1111/jvh.12448. [PMID: 26280786] - Yasushi Rino, Norio Yukawa, Naoto Yamamoto. Does herbal medicine reduce the risk of hepatocellular carcinoma?.
World journal of gastroenterology.
2015 Oct; 21(37):10598-603. doi:
10.3748/wjg.v21.i37.10598. [PMID: 26457019] - Massimo Colombo. Interferon-free therapy for hepatitis C: The hurdles amid a golden era.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
2015 Sep; 47(9):727-33. doi:
10.1016/j.dld.2015.04.003. [PMID: 25937625] - Masashi Mizokami, Osamu Yokosuka, Tetsuo Takehara, Naoya Sakamoto, Masaaki Korenaga, Hitoshi Mochizuki, Kunio Nakane, Hirayuki Enomoto, Fusao Ikeda, Mikio Yanase, Hidenori Toyoda, Takuya Genda, Takeji Umemura, Hiroshi Yatsuhashi, Tatsuya Ide, Nobuo Toda, Kazushige Nirei, Yoshiyuki Ueno, Yoichi Nishigaki, Juan Betular, Bing Gao, Akinobu Ishizaki, Masa Omote, Hongmei Mo, Kim Garrison, Phillip S Pang, Steven J Knox, William T Symonds, John G McHutchison, Namiki Izumi, Masao Omata. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.
The Lancet. Infectious diseases.
2015 Jun; 15(6):645-53. doi:
10.1016/s1473-3099(15)70099-x. [PMID: 25863559] - Anita Kohli, Anuoluwapo Osinusi, Zayani Sims, Amy Nelson, Eric G Meissner, Lisa L Barrett, Dimitra Bon, Miriam M Marti, Rachel Silk, Colleen Kotb, Chloe Gross, Tim A Jolley, Sreetha Sidharthan, Tess Petersen, Kerry Townsend, D'Andrea Egerson, Rama Kapoor, Emily Spurlin, Michael Sneller, Michael Proschan, Eva Herrmann, Richard Kwan, Gebeyehu Teferi, Rohit Talwani, Gabbie Diaz, David E Kleiner, Brad J Wood, Jose Chavez, Stephen Abbott, William T Symonds, G Mani Subramanian, Phillip S Pang, John McHutchison, Michael A Polis, Anthony S Fauci, Henry Masur, Shyam Kottilil. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study.
Lancet (London, England).
2015 Mar; 385(9973):1107-13. doi:
10.1016/s0140-6736(14)61228-9. [PMID: 25591505] - Anu Osinusi, Kerry Townsend, Anita Kohli, Amy Nelson, Cassie Seamon, Eric G Meissner, Dimitra Bon, Rachel Silk, Chloe Gross, Angie Price, Mohammad Sajadi, Sreetha Sidharthan, Zayani Sims, Eva Herrmann, John Hogan, Gebeyehu Teferi, Rohit Talwani, Michael Proschan, Veronica Jenkins, David E Kleiner, Brad J Wood, G Mani Subramanian, Phillip S Pang, John G McHutchison, Michael A Polis, Anthony S Fauci, Henry Masur, Shyam Kottilil. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection.
JAMA.
2015 Mar; 313(12):1232-9. doi:
10.1001/jama.2015.1373. [PMID: 25706232] - Bennett C Noell, Siddesh V Besur, Andrew S deLemos. Changing the face of hepatitis C management - the design and development of sofosbuvir.
Drug design, development and therapy.
2015; 9(?):2367-74. doi:
10.2147/dddt.s65255. [PMID: 25987834] - Eric G Meissner, Jérémie Decalf, Armanda Casrouge, Henry Masur, Shyam Kottilil, Matthew L Albert, Darragh Duffy. Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy.
PloS one.
2015; 10(7):e0133236. doi:
10.1371/journal.pone.0133236. [PMID: 26181438] - Anu Osinusi, Anita Kohli, Miriam M Marti, Amy Nelson, Xiaozhen Zhang, Eric G Meissner, Rachel Silk, Kerry Townsend, Phillip S Pang, G Mani Subramanian, John G McHutchison, Anthony S Fauci, Henry Masur, Shyam Kottilil. Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study.
Annals of internal medicine.
2014 Nov; 161(9):634-8. doi:
10.7326/m14-1211. [PMID: 25364884] - Jay H Hoofnagle, Averell H Sherker. Therapy for hepatitis C--the costs of success.
The New England journal of medicine.
2014 Apr; 370(16):1552-3. doi:
10.1056/nejme1401508. [PMID: 24725236] - John O Link, James G Taylor, Lianhong Xu, Michael Mitchell, Hongyan Guo, Hongtao Liu, Darryl Kato, Thorsten Kirschberg, Jianyu Sun, Neil Squires, Jay Parrish, Terry Kellar, Zheng-Yu Yang, Chris Yang, Mike Matles, Yujin Wang, Kelly Wang, Guofeng Cheng, Yang Tian, Erik Mogalian, Elsa Mondou, Melanie Cornpropst, Jason Perry, Manoj C Desai. Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection.
Journal of medicinal chemistry.
2014 03; 57(5):2033-46. doi:
10.1021/jm401499g. [PMID: 24320933] - Huiling Yang, Margaret Robinson, Amoreena C Corsa, Betty Peng, Guofeng Cheng, Yang Tian, Yujin Wang, Rowchanak Pakdaman, Marian Shen, Xiaoping Qi, Hongmei Mo, Chin Tay, Steve Krawczyk, X Christopher Sheng, Choung U Kim, Chris Yang, William E Delaney. Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451.
Antimicrobial agents and chemotherapy.
2014; 58(2):647-53. doi:
10.1128/aac.00487-13. [PMID: 23939899] - Eric J Lawitz, Daniel Gruener, John M Hill, Thomas Marbury, Lisa Moorehead, Anita Mathias, Guofeng Cheng, John O Link, Kelly A Wong, Hongmei Mo, John G McHutchison, Diana M Brainard. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.
Journal of hepatology.
2012 Jul; 57(1):24-31. doi:
10.1016/j.jhep.2011.12.029. [PMID: 22314425]